Nasal Septal Perforation in Propylthiouracil-Induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Here, we present the case of a 29-year-old woman with nasal septal perforation and positive myeloperoxidase- (MPO-) anti-neutrophil cytoplasmic antibody (ANCA). She had been diagnosed with Graves’ disease and had been treated with propylthiouracil (PTU) for 14 months. A biopsy of the nasal septum re...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in rheumatology 2018, Vol.2018 (2018), p.1-4
Main Authors: Harigae, Hideo, Fujii, Hiroshi, Shirota, Yuko, Fujita, Yoko, Hoshi, Yousuke, Shirai, Tsuyoshi, Ishii, Yusho, Ishii, Tomonori
Format: Article
Language:English
Subjects:
Antibodies
Case Report
Case reports
Cocaine
Disease
Endocarditis
Endoscopy
Fever
Health aspects
Hospitals
Neutrophils
NMR
Nose
Nuclear magnetic resonance
Otolaryngology
Otology
Patients
Pneumonia
Propylthiouracil
Rheumatology
Thyroid gland
Tuberculosis
Vasculitis
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Here, we present the case of a 29-year-old woman with nasal septal perforation and positive myeloperoxidase- (MPO-) anti-neutrophil cytoplasmic antibody (ANCA). She had been diagnosed with Graves’ disease and had been treated with propylthiouracil (PTU) for 14 months. A biopsy of the nasal septum revealed an infiltration of inflammatory cells, with no evidence of malignancy or granulomatous change. Because of the use of PTU, destructive nasal lesion, and positive MPO-ANCA, she was diagnosed with drug-induced ANCA-associated vasculitis (AAV) and was treated with prednisolone and methotrexate after the cessation of PTU. Although PTU is known to be the medicine that induces drug-induced AAV, the manifestation of nasal septal perforation in drug-induced AAV is poorly identified. This is the rare case of drug-induced AAV which manifested only nasal septal perforation.
ISSN:2090-6889
2090-6897
DOI:10.1155/2018/8192021